Earlier ARV treatment saves lives
Last week, an independent data and safety monitoring board recommended immediately ending a trial being carried out by the Haitian Group for the Study of Kaposi’s Sarcoma and Immune Deficiency Disorders (GHESKIO) Centers, because the evidence in favour of earlier treatment was so overwhelming.
The study was being run in the capital, Port-au-Prince, with funding from the US National Institute of Allergy and Infectious Diseases (NIAID).
Recent studies in the developed world have found that starting HIV-infected patients on treatment when their CD4 cell count (a measure of immune system strength) drops below 350 greatly reduces AIDS-related mortality. Waiting until it fell below 200 was previously thought to be optimal.
However, some experts argued that these findings could not be extrapolated to resource-limited settings because they were based on patient records rather than a large, randomised trial in a poor country.
The trial in Haiti, known as CIPRA HT 001, started in 2005, when 816 HIV-positive participants with CD4 counts between 200 and 350 were recruited. Half of them were randomly assigned to begin ARV treatment immediately; the other half were to start treatment only when their CD4 counts dropped below 200, in line with national treatment guidelines in Haiti and many other developing countries.
By the time the trial was stopped, six participants in the group that began treatment earlier had died, compared to 23 in the group that started treatment later.
The number of patients who contracted tuberculosis (TB), a common and often deadly opportunistic infection in people living with HIV, was 18 in the early-treatment group, compared to 36 in the other group.
The monitoring board recommended that all the trial participants now be offered ARV treatment and followed for 12 months to ensure that they adhered to the timetable for taking their medication.
“The public health community now has evidence from a randomized, controlled clinical trial ‘ the gold standard ‘ that starting ART [antiretroviral treatment] at CD4 cell counts between 200 and 350 in resource-limited settings yields better health outcomes than deferring treatment until CD4 cell counts drop below 200,” said NIAID Director Anthony S. Fauci in a statement.
Although some countries changed their ARV treatment protocols after evidence from earlier studies, many in the developing world still wait until patients have a CD4 count of 200 or less to begin treatment. The study investigators were confident that many more countries would revise their treatment guidelines.
Carl Dieffenbach, director of the NIAID Division of AIDS, noted that raising the threshold for starting ARV treatment would greatly increase the number of people needing medication, and the need for the global community to provide more support to buy ARVs.
See also: SOUTH AFRICA: Government urged to raise treatment standards
This feature is used with permission from IRIN/PlusNews – www.plusnews.org
Author
Health-e News is South Africa's dedicated health news service and home to OurHealth citizen journalism. Follow us on Twitter @HealtheNews
Republish this article
This work is licensed under a Creative Commons Attribution-NoDerivatives 4.0 International License.
Unless otherwise noted, you can republish our articles for free under a Creative Commons license. Here’s what you need to know:
You have to credit Health-e News. In the byline, we prefer “Author Name, Publication.” At the top of the text of your story, include a line that reads: “This story was originally published by Health-e News.” You must link the word “Health-e News” to the original URL of the story.
You must include all of the links from our story, including our newsletter sign up link.
If you use canonical metadata, please use the Health-e News URL. For more information about canonical metadata, click here.
You can’t edit our material, except to reflect relative changes in time, location and editorial style. (For example, “yesterday” can be changed to “last week”)
You have no rights to sell, license, syndicate, or otherwise represent yourself as the authorized owner of our material to any third parties. This means that you cannot actively publish or submit our work for syndication to third party platforms or apps like Apple News or Google News. Health-e News understands that publishers cannot fully control when certain third parties automatically summarise or crawl content from publishers’ own sites.
You can’t republish our material wholesale, or automatically; you need to select stories to be republished individually.
If you share republished stories on social media, we’d appreciate being tagged in your posts. You can find us on Twitter @HealthENews, Instagram @healthenews, and Facebook Health-e News Service.
You can grab HTML code for our stories easily. Click on the Creative Commons logo on our stories. You’ll find it with the other share buttons.
If you have any other questions, contact info@health-e.org.za.
Earlier ARV treatment saves lives
by Health-e News, Health-e News
June 12, 2009